Valvular heart disease
Conditions
Interventions
Control group (group C):Bilateral ultrasound-guided bilateral parasternal plane block with a total volume of 40 mL of saline solution
Ropivacaine group (group P) :Bilateral ultrasound-guided bilateral parasternal plane block with a total volume of 40 mL of 0.4% ropivacaine
Ropivacaine-dexmedetomidine group (group PD) :Bilateral ultrasound-guided bilateral parasternal plane block with a total volume of 40 mL of 0.4% ropivacaine with 0.2 µg/kg dexmedetomidine
Sponsors
The People's Hospital of Guangxi Zhuang Autonomous Region
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 20 to 65 years 2. No gender limitation 3. ASA class ? or ?, and NYHA class ? or ? 4. Normal cognitive 5. Mitral and aortic valve replacement
Exclusion criteria
Exclusion criteria: 1. Malignant tumor 2. Serious infection 3. Preexisting major liver, kidney or lung disease, pulmonary hypertension, or abnormal blood clotting function 4. Cardiac reoperation 5. Chronic pain syndrome 6. Application of chronic anti-inflammatory drugs and opioid drugs 7. Individuals with mental illness who cannot cooperate 8. Blood loss is greater than 50% blood volume 9. Maternal 10. Experimental drug allergy 11. Peripheral neuropathy 12. Immunosuppressive therapy or hormone therapy 13. Refusal to participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dosage of analgesics used during operation and 24h after operation;VAS scores;Bruggrmann comfort scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| PCA bolus;Rapid rehabilitation indicators;Ramsay scores;Duration of nerve block;Adverse reaction indicators; | — |
Countries
China
Contacts
Public ContactLi Yanru
The People's Hospital of Guangxi Zhuang Autonomous Region
Outcome results
None listed